Shares of Puma Biotechnology (NYSE:PBYI) are up a whopping 263% premarket on robust volume. Investors are piling in after the company announced positive Phase 3 results for its breast cancer drug candidate. The price jump represents a tidy $2.9B increase in Puma's market cap.